| |
Institute
of Pathology (LJJ, SL), CHUV, University of Lausanne; Neurosurgery Division
(MFH), CHUV, Lausanne, Switzerland; and INSERM U36 (FP), Collège
de France, Paris, France
|
| |
SUMMARY:
Angiotensin peptides are potent vasoconstrictors, cell growth factors,
and neuromodulators in normal and pathological situations. To assess the
potential role of the angiotensins in brain tumor-associated vessels,
the expression of the enzymes of the angiotensin cascade were evaluated
in these tumors. The production of these bioactive peptides is dependent
on the activities of exopeptidases, including several aminopeptidases
and carboxypeptidases, producing angiotensin (Ang) I, II, III, IV and
Ang 1-7. Human cerebral parenchymal and glioblastoma cells expressed renin,
and tumor vasculature, but not glioblastoma cells, expressed angiotensin-converting
enzyme. High aminopeptidase A (APA) activity, but no aminopeptidase N/B
activity, was observed in human brain tumor vasculature, suggesting a
predominant production of Ang III. Grafting of rat glioma cells in rat
brains yielded tumors with high APA and low aminopeptidase N/B activities
in tumor vessels, confirming human results. Tumor growth and APA activity
in tumor vessels were not affected by chronic angiotensin-converting enzyme
inhibition. The brain-derived EC219 endothelial cells expressed high APA
activity, which was not involved in endothelial cell proliferation, but
was down-regulated by exposure of cells to transforming growth factor-b
(TGFb) or to TGFb-secreting
tumor cells, suggesting a role for this peptide in the control of APA
activity in cerebral vasculature. Thus, APA is a potential marker of chronic
dysfunction, involving loss of TGFb function,
of the metabolic blood-brain barrier, but not of neovascularization.
|